Mumbai, April 11 -- The board of directors accepted Hrosz's resignation during a meeting held on 9 April and expressed appreciation for his significant contributions during his tenure. Hrosz will cease to be a key managerial personnel, senior management personnel, and a member of board committees at the close of business hours on 30 April 2025.
Further, the board approved Hrosz's appointment as an additional non-executive director effective 1 May 2025, subject to shareholder approval, upon the recommendation of the nomination and remuneration committee (NRC).
Sanofi India is among the leading multinational companies in the Indian pharmaceutical market. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, t...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.